Healthcare Webinars

The Mental Health Parity and Addiction Equity Act (MHPAEA) requires health plans and insurers to offer mental health coverage in “parity” with a plan’s medical or surgical coverage. In 2024, as the post-COVID era brings a national reckoning with mental health issues, mental health parity has risen to the forefront of federal and state regulatory priorities. Significant changes to mental health parity are expected in 2024 and beyond, as federal and state agencies move to enforce existing requirements and finalize proposed regulations. At the same time, federal courts continue to grapple with increasing private litigation driven by alleged violations of MHPAEA rules. In a new webinar, Manatt will map the current regulatory and litigation landscape and its implications for stakeholders and look ahead at how to prepare your organization for upcoming developments and challenges.

Join us for an informative webinar on reducing non-labor cost savings for purchased services, physician preference items, and pharmacy spend — three significant cost drivers for hospitals. Using real-world examples, we will share strategies and insights on purchased services cost savings initiatives, demonstrate how we collaborate with physicians to substantially reduce PPIs, and discuss transformative strategies for reducing pharmacy drug costs and maximizing revenue.

WEBINAR Healthcare Data: Your Secret Weapon for Market Expansion, Market Segmentation, and Go-to-Market SuccessIn the rapidly evolving healthcare landscape, staying ahead is not just an advantage—it's a necessity. In Part 1 of our two-part webinar series, we’ll share how the power of healthcare data can transform your go-to-market strategy. By the end of this session, you'll have a clear roadmap for market expansion, market segmentation, and go-to-market success. Don't miss this opportunity to turn healthcare data into your competitive advantage! Register for our webinar! By submitting this form you agree to our Privacy Policy.

Join Dr Brukner and globally renowned nutritional psychiatrist Dr Georgia Ede as they explore the surprising link between food and mental health and gain practical insights into adopting a brain-boosting diet.

Join us for an enlightening webinar where we'll address your burning questions about intimate wellness and treatment options. Dr. James and Dr. Salazar Valdes will provide valuable insights and discuss the latest advancements in the field. Register now to secure your spot!

The tumor microenvironment is a complex mix of cancer cells, immune cells, and other components that all play a part in tumor progression, metastasis, and therapy responses. Understanding the highly dynamic nature of the tumor microenvironment and the factors that influence those changes is essential for developing effective precision oncology therapies. Innovations in computational pathology and artificial intelligence, coupled with novel multiplex biomarker assays, are critical to fostering that understanding. Together, they are paving the way for scientists to better characterize the unique cancer cell populations, spatial relationships, and differences in immune responses in the tumor microenvironment.In this GEN webinar, Michael Downing, Senior Image Analysis Scientist at Ultivue, will review the state of the field and introduce Ultivue’s two core platform technologies: InSituPlex® assays, and its proprietary Spatial Image Analysis pipeline featuring UltiStacker.AI™ and UltiAnalyzer.AI™. He will also explain how these technologies work together to provide high confidence insights from tumor data for scientists developing precision cancer therapies.Topics covered in the webinar will include:How AI-supported spatial image analysis together with Ultivue’s InSituPlex assays deliver accurate and scalable insights into the biology of the tumor microenvironment.How Ultivue’s 12-plex assay verification demonstrates its readiness to provide a comprehensive view of the tumor microenvironment.A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

The field of biosimilars, which seeks to offer cost-effective alternatives to biologic drugs, has garnered significant attention in recent years. This report aims to provide an in-depth analysis of the biosimilar industry, tracing its evolution, examining its current market status over the past three years, and exploring future opportunities. Omnitrope's launch in 2006 was a pivotal moment for biosimilars, introducing them as viable options in healthcare. Initial regulatory hurdles were substantial, as biosimilar guidelines were nascent. The industry saw a turning point with the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) establishing a comprehensive approval pathway, which has since facilitated the entry of numerous biosimilars into the market. This report details the biosimilars approved up to the present, segmented by therapeutic application—such as treatments for growth hormone deficiency, anaemia, and autoimmune diseases. We highlight the first biosimilar moieties launched between 2021 and 2023, including their regulatory approvals and market impact on their reference drugs. The current regulatory environment and market dynamics for biosimilars are evaluated to understand their position in the healthcare landscape. We will analyze the upcoming biosimilars anticipated for launch in the upcoming years and their respective focused indications. The webinar offers a comprehensive analysis of the biosimilar landscape, from its inception to its future prospects. The increasing focus on research and development, combined with regulatory advancements, underscores the significant role biosimilars will play in enhancing patient access to affordable, effective treatments.

In the United States, public health and health care delivery have largely taken different and siloed approaches, with health care focused on the treatment of individuals and public health centered on the total population within a geographic region. Collaboration between the sectors is essential to advancing both health outcomes and equity—a lesson driven home during the COVID-19 pandemic. In a new webinar, Manatt Health will provide an in-depth look at the innovative ways California health agencies are working together to bridge the gap between public health and managed care health care delivery—and what other states can learn from the California model.

We are delighted to invite all from the HSE organisation, HealthSciencesLibrariesGroup and team members to attend the online launch of the #hselibrary strategy.

With presentations from experts at Atrium Wake Forest Baptist Health, this webinar will provide health system professionals with knowledge on how adopting a cochlear implant robotics program can help to position their health system's cochlear implant program as the program of choice for patients in their region. Our distinguished presenters, including an Associate Vice President of Regional Strategy and Planning and an Associate Professor of Otology/Neurotology, bring extensive expertise and firsthand experience to the discussion. They will delve into the strategic advantages, economic benefits, and clinical outcomes associated with integrating a cochlear implant robotics program into healthcare systems. Key highlights of the webinar include: 1. Strategic insights into positioning healthcare systems as leaders on patient access to advancements in implantable hearing technology 2. Analysis showcasing the economic case for cochlear implant robotics programs 3. Clinical evidence of robotic-assisted cochlear implantation vs. manual implantation techniques This webinar is tailored for professionals working within healthcare systems, particularly those involved in strategic planning, otology/neurotology, and related fields. Whether you're exploring innovative solutions to enhance patient care or seeking to stay ahead of industry trends, this webinar is an invaluable opportunity to gain knowledge and insights from leaders at the forefront of hearing healthcare. Don't miss out on this exclusive opportunity to discover the strategic, economic, and clinical rationale behind adopting a cochlear implant robotics program.